Image Credit: Roche Sequencing and Life Science The frequency of SNV alleles is consistent across DNA and RNA readings. Using the KAPA Total Prep FFPE methodology and the KAPA HyperCap Oncology ...

Roche is the latest company trying to tap into the highly lucrative weight-loss drug market by fast-tracking its own candidates. The pharmaceutical giant said that its CT-388 drug is now ...

Darragh Roche is a U.S. News Reporter based in Limerick, Ireland. His focus is reporting on U.S. politics. He has covered the Biden administration, election polling and the U.S. Supreme Court.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Roche plans to fast-track its anti-obesity drugs to challenge rivals Eli Lilly and Novo Nordisk in the ...

July 29 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab plans to accelerate the development of its anti-obesity drugs to challenge rivals like Eli Lilly (LLY.N), opens new tab and Novo ...

Investor and strategist David Roche expects the economy to enter a bear market in 2025, he said on Monday. The market will be driven down by rate cuts that will disappoint, a slowing economy and ...

Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for ...

Roche (ROG.S), opens new tab on Thursday raised its full-year earnings forecast after exceeding expectations for the first half, driven by strong demand for newer drugs such as eye medicine Vabysmo.

06 February 2024, Baden-Württemberg, Mannheim: Daniela Kahlert, Managing Director of Roche ... [+] Diagnostics Deutschland GmbH, stands on a staircase at Roche Pharma's annual press conference.

Shares of Roche (OTCQX:RHHBY) rose last week to levels last seen in late 2022 after the company reported positive phase 1 results of CT-996, its oral GLP-1 agonist for the treatment of obesity.

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) plans to fast-track its anti-obesity drugs to challenge market leaders Eli Lilly (LLY) and Novo Nordisk (NVO), the Financial Times reported on Monday. The Swiss ...